Elevance Health Inc. (ELV) Cash Flow Statement
Where ELV’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $4.29B −26.1% vs 2024
- Capital expenditures
- $1.12B 0.6% of revenue
- Free cash flow
- $3.17B 1.6% margin
- Returned to shareholders
- $4.13B 130% of free cash flow
- Change in cash
- $1.20B cash at year-end $9.49B
Drawn to scale: where the cash came from and how it was used. Hover for values.
ELV operating cash flow, capex and free cash flow
ELV cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $3.20B2016 | $4.29B2025 | +3.3%/yr | |
| Capital expenditures | $583.6M2016 | $1.12B2025 | +7.5%/yr | |
| Free cash flow | $2.62B2016 | $3.17B2025 | +2.2%/yr | |
| Free cash flow margin | 3.1%2016 | 1.6%2025 | −1.5 pts | |
| Operating cash flow / net income | 1.302016 | 0.762025 | −0.54 | |
| Stock-based compensation | $164.6M2016 | $276.0M2025 | +5.9%/yr | |
| Dividends paid | $684.0M2016 | $1.53B2025 | +9.3%/yr | |
| Share buybacks (net) | $67.0M2016 | $2.60B2025 | +50.2%/yr | |
| Capex / revenue | 0.7%2016 | 0.6%2025 | −0.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ELV cash flow by activity
ELV net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ELV cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $5.66B | $5.97B | $5.99B | $6.02B | $6.09B | $4.57B | $4.81B | $3.75B | $3.84B | $2.47B |
| Depreciation & amortization | $1.55B | $1.39B | $1.75B | $1.68B | $1.30B | $1.15B | $1.13B | $1.13B | $891.0M | $912.0M |
| Stock-based compensation | $276.0M | $191.0M | $289.0M | $264.0M | $255.0M | $283.0M | $294.0M | $226.0M | $169.6M | $164.6M |
| Change in working capital | −$3.28B | −$1.72B | −$535.0M | $253.0M | $784.0M | $5.20B | −$192.0M | −$1.60B | $367.9M | −$574.9M |
| Other non-cash items | $84.0M | −$28.0M | $575.0M | $188.0M | −$72.0M | −$524.0M | $19.0M | $321.0M | −$1.09B | $233.0M |
| Cash from operating activities | $4.29B | $5.81B | $8.06B | $8.40B | $8.36B | $10.69B | $6.06B | $3.83B | $4.18B | $3.20B |
| Investing activities | ||||||||||
| Capital expenditures | −$1.12B | −$1.26B | −$1.30B | −$1.15B | −$1.09B | −$1.02B | −$1.08B | −$1.21B | −$790.2M | −$583.6M |
| Investments (net) | $69.0M | −$5.17B | −$4.25B | −$4.56B | −$4.06B | −$14.75B | −$2.46B | $16.0M | −$2.85B | −$149.3M |
| Acquisitions & other investing | −$297.0M | $1.26B | −$22.0M | $1.15B | −$4.50B | $8.45B | $743.0M | −$67.0M | −$1.44B | $219.0M |
| Cash from investing activities | −$1.34B | −$5.17B | −$5.57B | −$4.56B | −$9.64B | −$7.32B | −$2.79B | −$1.26B | −$5.08B | −$513.9M |
| Financing activities | ||||||||||
| Dividends paid | −$1.53B | −$1.51B | −$1.40B | −$1.23B | −$1.10B | −$954.0M | −$818.0M | −$776.0M | −$704.9M | −$684.0M |
| Share repurchases & issuance (net) | −$2.60B | −$2.90B | −$2.68B | −$2.32B | −$1.90B | −$2.70B | −$1.70B | −$1.69B | −$2.00B | −$67.0M |
| Net borrowing (repayment) | $2.33B | $5.56B | $739.0M | $1.79B | $3.67B | −$298.0M | $438.0M | −$1.29B | $3.72B | $360.6M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.25B | $0 | $0 |
| Other financing | $69.0M | $39.0M | −$17.0M | $432.0M | −$248.0M | $1.39B | −$185.0M | $265.0M | −$594.7M | −$342.5M |
| Cash from financing activities | −$1.74B | $1.19B | −$3.35B | −$1.32B | $423.0M | −$2.57B | −$2.27B | −$2.24B | $426.9M | −$732.9M |
| Summary | ||||||||||
| Net change in cash | $1.20B | $1.76B | −$861.0M | $2.51B | −$861.0M | $804.0M | $1.00B | $325.0M | −$466.4M | $1.96B |
| Cash at end of period | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B | $5.74B | $4.94B | $3.93B | $3.61B | $4.08B |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B | $7.28B | $9.67B | $4.98B | $2.62B | $3.39B | $2.62B |
| Free cash flow margin | 1.6% | 2.6% | 3.9% | 4.6% | 5.2% | 7.9% | 4.8% | 2.8% | 3.8% | 3.1% |
| Capex / revenue | 0.6% | 0.7% | 0.8% | 0.7% | 0.8% | 0.8% | 1.0% | 1.3% | 0.9% | 0.7% |
| Operating cash flow / net income | 0.76 | 0.97 | 1.35 | 1.40 | 1.37 | 2.34 | 1.26 | 1.02 | 1.09 | 1.30 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $1.45B | $1.76B | $546.0M | $1.19B | $1.74B | $2.18B | $413.0M | $1.01B | $2.30B | $2.25B | $831.0M | $1.30B |
| Depreciation & amortization | $366.0M | $354.0M | $406.0M | $387.0M | $380.0M | $373.0M | $398.0M | $329.0M | $335.0M | $331.0M | $424.0M | $426.0M |
| Stock-based compensation | $75.0M | $55.0M | $30.0M | $84.0M | $81.0M | $81.0M | −$29.0M | $66.0M | $92.0M | $62.0M | $72.0M | $78.0M |
| Change in working capital | $38.0M | $1.06B | −$524.0M | −$750.0M | −$218.0M | −$1.78B | −$18.0M | $1.24B | −$1.96B | −$988.0M | −$4.36B | $210.0M |
| Other non-cash items | −$20.0M | $1.11B | −$374.0M | $227.0M | $67.0M | $164.0M | −$58.0M | $32.0M | −$326.0M | $324.0M | $58.0M | $599.0M |
| Cash from operating activities | $1.91B | $4.33B | $84.0M | $1.14B | $2.05B | $1.02B | $706.0M | $2.68B | $447.0M | $1.98B | −$2.97B | $2.61B |
| Investing activities | ||||||||||||
| Capital expenditures | −$287.0M | −$235.0M | −$293.0M | −$360.0M | −$267.0M | −$196.0M | −$322.0M | −$332.0M | −$323.0M | −$279.0M | −$326.0M | −$319.0M |
| Investments (net) | $276.0M | −$1.09B | $481.0M | −$1.22B | −$687.0M | $103.0M | −$1.64B | −$401.0M | −$818.0M | −$2.31B | −$1.03B | −$687.0M |
| Acquisitions & other investing | $170.0M | −$318.0M | $276.0M | $360.0M | $267.0M | $196.0M | $322.0M | $332.0M | $323.0M | $279.0M | $326.0M | −$3.54B |
| Cash from investing activities | $159.0M | −$1.64B | $464.0M | −$1.22B | −$687.0M | $103.0M | −$1.64B | −$401.0M | −$818.0M | −$2.31B | −$1.03B | −$4.54B |
| Financing activities | ||||||||||||
| Dividends paid | −$373.0M | −$376.0M | −$377.0M | −$381.0M | −$385.0M | −$386.0M | −$373.0M | −$378.0M | −$378.0M | −$379.0M | −$346.0M | −$348.0M |
| Share repurchases & issuance (net) | −$234.0M | −$1.12B | −$471.0M | −$876.0M | −$378.0M | −$880.0M | −$1.81B | −$60.0M | −$463.0M | −$566.0M | −$928.0M | −$480.0M |
| Net borrowing (repayment) | −$753.0M | −$1.33B | $1.59B | $1.36B | $195.0M | −$819.0M | $3.82B | −$358.0M | — | — | — | −$197.0M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$134.0M | $313.0M | −$507.0M | $140.0M | $260.0M | $176.0M | −$227.0M | −$119.0M | $1.51B | $977.0M | $880.0M | $31.0M |
| Cash from financing activities | −$1.49B | −$2.52B | $236.0M | $243.0M | −$308.0M | −$1.91B | $1.41B | −$915.0M | $668.0M | $32.0M | −$394.0M | −$994.0M |
| Summary | ||||||||||||
| Net change in cash | $575.0M | $166.0M | $778.0M | $153.0M | $1.06B | −$788.0M | $422.0M | $1.37B | $271.0M | −$300.0M | −$4.39B | $928.0M |
| Cash at end of period | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | $7.50B | $8.29B | $7.87B | $6.50B | $6.23B | $6.53B | $10.92B |
| Free cash flow | $1.63B | $4.10B | −$209.0M | $775.0M | $1.79B | $821.0M | $384.0M | $2.35B | $124.0M | $1.70B | −$3.30B | $2.29B |
| Free cash flow margin | 3.2% | 8.2% | −0.4% | 1.5% | 3.6% | 1.7% | 0.8% | 5.2% | 0.3% | 4.0% | −7.7% | 5.4% |
| Capex / revenue | 0.6% | 0.5% | 0.6% | 0.7% | 0.5% | 0.4% | 0.7% | 0.7% | 0.7% | 0.7% | 0.8% | 0.7% |
| Operating cash flow / net income | 1.32 | 2.46 | 0.15 | 0.96 | 1.18 | 0.47 | 1.71 | 2.66 | 0.19 | 0.88 | −3.58 | 2.01 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ELV cash generation
In fiscal 2025 (ended December 31, 2025), Elevance Health generated $4.3 billion of cash from operations (down 26.1%) and spent $1.1 billion on capital expenditures, leaving free cash flow of $3.2 billion, 1.6% of revenue. It returned $4.1 billion to shareholders through dividends ($1.5 billion) and net share buybacks ($2.6 billion). Cash and equivalents rose by $1.2 billion over the year.
Related: ELV income statement, ELV balance sheet, ELV dividend history. See the ELV stock overview for the latest quote and news.
ELV cash flow FAQ
What is Elevance Health's free cash flow?
Elevance Health's free cash flow was $3.2 billion in fiscal 2025: $4.3 billion of operating cash flow minus $1.1 billion of capital expenditures It was $4.6 billion a year earlier..
How much cash does Elevance Health generate from operations?
Elevance Health generated $4.3 billion of cash from operating activities in fiscal 2025, 0.76 times its net income of $5.7 billion.
How much does Elevance Health spend on capital expenditures?
Elevance Health spent $1.1 billion on capital expenditures in fiscal 2025, 0.6% of revenue, compared with $1.3 billion the year before.
How much stock does Elevance Health buy back?
Elevance Health spent $2.6 billion on net share repurchases in fiscal 2025.
How much does Elevance Health pay in dividends?
Elevance Health paid $1.5 billion in dividends in fiscal 2025, 48.2% of free cash flow.